References
1. Abdelwahab SF. Cellular immune response to hepatitis-C-virus in
subjects without viremia or seroconversion: is it important? Infectious
agents and cancer 2016; 11 :23.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for
the Study of Liver D. Diagnosis, management, and treatment of hepatitis
C: an update. Hepatology 2009; 49 :1335-74.
3. Rosen HR. Clinical practice. Chronic hepatitis C infection. N
Engl J Med 2011; 364 :2429-38.
4. Li K, Chen Z, Kato N, Gale M, Jr., Lemon SM. Distinct poly(I-C) and
virus-activated signaling pathways leading to interferon-beta production
in hepatocytes. J Biol Chem 2005; 280 :16739-47.
5. Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M, Szczeponek A,
Gerken G, Schlaak JF. Toll-like receptor-stimulated non-parenchymal
liver cells can regulate hepatitis C virus replication. J Hepatol
2008; 48 :914-22.
6. Dolganiuc A, Garcia C, Kodys K, Szabo G. Distinct Toll-like receptor
expression in monocytes and T cells in chronic HCV infection.World J Gastroenterol 2006; 12 :1198-204.
7. Geiss GK, Carter VS, He Y, Kwieciszewski BK, Holzman T, Korth MJ,
Lazaro CA, Fausto N, Bumgarner RE, Katze MG. Gene expression profiling
of the cellular transcriptional network regulated by alpha/beta
interferon and its partial attenuation by the hepatitis C virus
nonstructural 5A protein. J Virol 2003; 77 :6367-75.
8. Shiina M, Rehermann B. Cell culture-produced hepatitis C virus
impairs plasmacytoid dendritic cell function. Hepatology 2008;47 :385-95.
9. Foy E, Li K, Wang C, Sumpter R, Jr., Ikeda M, Lemon SM, Gale M, Jr.
Regulation of interferon regulatory factor-3 by the hepatitis C virus
serine protease. Science 2003; 300 :1145-8.
10. Otsuka M, Kato N, Moriyama M, Taniguchi H, Wang Y, Dharel N, Kawabe
T, Omata M. Interaction between the HCV NS3 protein and the host TBK1
protein leads to inhibition of cellular antiviral responses.Hepatology 2005; 41 :1004-12.
11. Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen X, Taguwa S, Moriishi K,
Takeuchi O, Kawai T, Kanto T, Hayashi N, Akira S, Matsuura Y. Hepatitis
C virus nonstructural protein 5A modulates the toll-like
receptor-MyD88-dependent signaling pathway in macrophage cell
lines. J Virol 2007; 81 :8953-66.
12. Fukuda K, Tsuchihara K, Hijikata M, Nishiguchi S, Kuroki T,
Shimotohno K. Hepatitis C virus core protein enhances the activation of
the transcription factor, Elk1, in response to mitogenic stimuli.Hepatology 2001; 33 :159-65.
13. Yonkers NL, Rodriguez B, Milkovich KA, Asaad R, Lederman MM, Heeger
PS, Anthony DD. TLR ligand-dependent activation of naive CD4 T cells by
plasmacytoid dendritic cells is impaired in hepatitis C virus
infection. J Immunol 2007; 178 :4436-44.
14. Hamdy S, Osman AM, Zakaria ZA, Galal I, Sobhy M, Hashem M, Allam WR,
Abdel-Samiee M, Rewisha E, Waked I, Abdelwahab SF. Association of
Toll-like receptor 3 and Toll-like receptor 9 single-nucleotide
polymorphisms with hepatitis C virus persistence among Egyptians.Arch Virol 2018; 163 :2433-42.
15. Davidson F, Simmonds P. Determination of HCV Genotypes by
RFLP. Methods Mol Med 1999; 19 :175-81.
16. Pandey S, Mittal B, Srivastava M, Singh S, Srivastava K, Lal P,
Mittal RD. Evaluation of Toll-like receptors 3 (c.1377C/T) and 9
(G2848A) gene polymorphisms in cervical cancer susceptibility.Mol Biol Rep 2011; 38 :4715-21.
17. Demirci FY, Manzi S, Ramsey-Goldman R, Kenney M, Shaw PS,
Dunlop-Thomas CM, Kao AH, Rhew EY, Bontempo F, Kammerer C, Kamboh MI.
Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor
9 (TLR9) polymorphisms in systemic lupus erythematosus. J
Rheumatol 2007; 34 :1708-11.
18. Abdelwahab SF, Zakaria Z, Sobhy M, Rewisha E, Mahmoud MA, Amer MA,
Del Sorbo M, Capone S, Nicosia A, Folgori A, Hashem M, El-Kamary SS.
Hepatitis C virus-multispecific T-cell responses without viremia or
seroconversion among Egyptian health care workers at high risk of
infection. Clin Vaccine Immunol 2012; 19 :780-6.
19. Farid A, Al-Sherbiny M, Osman A, Mohamed N, Saad A, Shata MT, Lee
DH, Prince AM, Strickland GT. Schistosoma infection inhibits cellular
immune responses to core HCV peptides. Parasite Immunol 2005;27 :189-96.
20. Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, Flavell
RA, Oldstone MB. Does Toll-like receptor 3 play a biological role in
virus infections? Virology 2004; 322 :231-8.
21. Takeuchi O, Hemmi H, Akira S. Interferon response induced by
Toll-like receptor signaling. J Endotoxin Res 2004;10 :252-6.
22. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC,
Gale M, Jr., Lemon SM. Immune evasion by hepatitis C virus NS3/4A
protease-mediated cleavage of the Toll-like receptor 3 adaptor protein
TRIF. Proc Natl Acad Sci U S A 2005; 102 :2992-7.
23. Chang S, Kodys K, Szabo G. Impaired expression and function of
toll-like receptor 7 in hepatitis C virus infection in human hepatoma
cells. Hepatology 2010; 51 :35-42.
24. Ranjith-Kumar CT, Miller W, Sun J, Xiong J, Santos J, Yarbrough I,
Lamb RJ, Mills J, Duffy KE, Hoose S, Cunningham M, Holzenburg A, Mbow
ML, Sarisky RT, Kao CC. Effects of single nucleotide polymorphisms on
Toll-like receptor 3 activity and expression in cultured cells. J
Biol Chem 2007; 282 :17696-705.
25. Geng PL, Song LX, An H, Huang JY, Li S, Zeng XT. Toll-Like Receptor
3 is Associated With the Risk of HCV Infection and HBV-Related
Diseases. Medicine (Baltimore) 2016; 95 :e2302.
26. Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, Hart J, Hagemann T,
Diaz-Lacava A, Baurecht HJ, Klopp N, Wagenpfeil S, Behrendt H, Bieber T,
Ring J, Illig T, Weidinger S. Putative association of a TLR9 promoter
polymorphism with atopic eczema. Allergy 2007;62 :766-72.
27. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S,
Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody
production in murine lupus. J Exp Med 2005; 202 :321-31.
28. Yusuf JH, Kaliyaperumal D, Jayaraman M, Ramanathan G, Devaraju P.
Genetic selection pressure in TLR9 gene may enforce risk for SLE in
Indian Tamils. Lupus 2017; 26 :307-10.
29. Medhi S, Deka M, Deka P, Swargiary SS, Hazam RK, Sharma MP, Gumma
PK, Asim M, Kar P. Promoter region polymorphism & expression profile of
toll like receptor-3 (TLR-3) gene in chronic hepatitis C virus (HCV)
patients from India. Indian J Med Res 2011; 134 :200-7.
30. Wei XS, Wei CD, Tong YQ, Zhu CL, Zhang PA. Single nucleotide
polymorphisms of toll-like receptor 7 and toll-like receptor 9 in
hepatitis C virus infection patients from central China. Yonsei
Med J 2014; 55 :428-34.
31. Ng MT, Van’t Hof R, Crockett JC, Hope ME, Berry S, Thomson J, McLean
MH, McColl KE, El-Omar EM, Hold GL. Increase in NF-kappaB binding
affinity of the variant C allele of the toll-like receptor 9 -1237T/C
polymorphism is associated with Helicobacter pylori-induced gastric
disease. Infect Immun 2010; 78 :1345-52.
32. Fischer J, Weber AN, Bohm S, Dickhofer S, El Maadidi S, Deichsel D,
Knop V, Klinker H, Moller B, Rasenack J, Wang L, Sharma M, Hinrichsen H,
Spengler U, Buggisch P, Sarrazin C, Pawlita M, Waterboer T, Wiese M,
Probst-Muller E, Malinverni R, Bochud PY, Gardiner CM, O’Farrelly C,
Berg T. Sex-specific effects of TLR9 promoter variants on spontaneous
clearance of HCV infection. Gut 2016.
33. Aslam N, Batool F, Iqbal MS, Ashfaq UA, Ayaz S, Khaliq S, Jahan S,
Ghani MU, Usman M. Analysis of toll-like receptors-9 (TLR9) gene
polymorphism (rs5743836) in Pakistani patients with HCV. Pak J
Pharm Sci 2018; 31 :2709-14.
34. Lange NE, Zhou X, Lasky-Su J, Himes BE, Lazarus R, Soto-Quiros M,
Avila L, Celedon JC, Hawrylowicz CM, Raby BA, Litonjua AA. Comprehensive
genetic assessment of a functional TLR9 promoter polymorphism: no
replicable association with asthma or asthma-related phenotypes.BMC Med Genet 2011; 12 :26.
35. Kikuchi K, Lian ZX, Kimura Y, Selmi C, Yang GX, Gordon SC,
Invernizzi P, Podda M, Coppel RL, Ansari AA, Ikehara S, Miyakawa H,
Gershwin ME. Genetic polymorphisms of toll-like receptor 9 influence the
immune response to CpG and contribute to hyper-IgM in primary biliary
cirrhosis. J Autoimmun 2005; 24 :347-52.
36. Chuang TH, Ulevitch RJ. Cloning and characterization of a sub-family
of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur
Cytokine Netw 2000; 11 :372-8.
37. Lai ZZ, Ni Z, Pan XL, Song L. Toll-like receptor 9 (TLR9) gene
polymorphisms associated with increased susceptibility of human
papillomavirus-16 infection in patients with cervical cancer. J
Int Med Res 2013; 41 :1027-36.
38. Tian S, Zhang L, Yang T, Wei X, Zhang L, Yu Y, Li Y, Cao D, Yang X.
The Associations between Toll-Like Receptor 9 Gene Polymorphisms and
Cervical Cancer Susceptibility. Mediators Inflamm 2018;2018 :9127146.